Европейский союз - литовский - EMA (European Medicines Agency)

instituto grifols s.a. - Žmogaus normalus imunoglobulinas - mucocutaneous lymph node syndrome; guillain-barre syndrome; bone marrow transplantation; purpura, thrombocytopenic, idiopathic; immunologic deficiency syndromes - imuninės serumai ir imunoglobulinai, - replacement therapy in adults, children and adolescents (0-18 years) in: , primary immunodeficiency syndromes with impaired antibody production;, hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic luekaemia, in whom prophylactic antibiotics have failed;, hypogammaglobulinaemia and recurrent bacterial infections in plateau-phase-multiple-myeloma patients who failed to respond to pneumococcal immunisation;, hypogammaglobulinaemia in patients after allogenic haematopoietic-stem-cell transplantation (hsct);, congenital aids with recurrent bacterial infections. , immunomodulation in adults, children and adolescents (0-18 years) in: , primary immune thrombocytopenia (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count;, guillain barré syndrome;, kawasaki disease.

Литва - литовский - SMCA (Valstybinė vaistų kontrolės tarnyba)

the simple pharma company limited - testosteronas - transderminis gelis - 20 mg/g - testosterone

Европейский союз - литовский - EMA (European Medicines Agency)

medac gesellschaft für klinische spezialpräparate mbh - carmustine - hodgkin disease; lymphoma, non-hodgkin - antinavikiniai vaistai - carmustine is indicated n adults in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery): , brain tumours (glioblastoma, brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases, secondary therapy in non-hodgkin’s lymphoma and hodgkin’s disease, as conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (hpct) in malignant haematological diseases (hodgkin’s disease / non-hodgkin’s lymphoma).

Европейский союз - литовский - EMA (European Medicines Agency)

bluebird bio (netherlands) b.v. - autologinės cd34+ ląstelių praturtintas gyventojų, kad yra kraujodaros kamieninių ląstelių transduced su lentiglobin bb305 lentiviral vektoriaus kodavimo beta-a-t87q-globino genų - beta-talasemija - other hematological agents - zynteglo yra nurodyta, gydomi pacientai, 12 metų ir vyresni, su perpylimu priklauso nuo β thalassaemia (tdt), kurie neturi β0/β0 genotipo, kuriems kraujodaros kamieninių ląstelių (ssk) transplantacija reikalinga, tačiau žmogaus leukocitų antigenų (Žla),-derinama, susijusių ssk donoro nėra.

Европейский союз - литовский - EMA (European Medicines Agency)

merial - eprinomectin - endektokidai - galvijai - apdorojant šiuos parazitus:virškinimo trakto apvaliųjų kirmėlių (suaugusiųjų ir l4):- ostertagia ostertagi/lyrata, cooperia oncophora/surnabada, c. punctata, haemonchus contortus, trichostrongylus axei, t. colubriformis, bunostomum phlebotomum, nematodirus helvetianus, oesophagostomum radiatumlungworm (suaugusiems ir l4):- dictyocaulus viviparuswarbles (parazitinės etapai):- hypoderma bovis, h. lineatummange erkės:- sarcoptes scabiei var. bovis utėlių: linognathus vituli, haematopinus eurysternus, solenoptes capillatushorn skrenda: haematobia irritansprevention iš reinfections su šių parazitų:- dictyocaulus viviparus, ostertagia ostertagi/lyrata, trichostrongylus colubriformis, haemonchus contortus, ir bunostomum phlebotomum;- oesophagostomum radiatum, cooperia oncophora/surnabada, c. punctata ir trichostrongylus axei.

Литва - литовский - SMCA (Valstybinė vaistų kontrolės tarnyba)

uab "interchemie werken "de adelaar" lt" (lietuva) - injekcinis tirpalas - buy abortion pill buy abortion pill1 ml yra: ivermektino - 10,0 mg. - galvijams, veršeliams, ožkoms, avims ir kiaulėms gydyti, sergant endoparazitų ir ektoparazitų (virškinimo trakto ir kvėpavimo takų nematodų, artropodų (musių, gylių), kraujasiurbių ir niežų erkių) sukeltomis ligomis ir sukėlėjų invazijai kontroliuoti.

Литва - литовский - SMCA (Valstybinė vaistų kontrolės tarnyba)

livisto int'l, s.l. (ispanija) - užpilamasis tirpalas - viename ml tirpalo yra: eprinomektino - 5 mg. - galvijams gydyti, esant užsikrėtimui eprinomektinui jautriais parazitais.

Литва - литовский - SMCA (Valstybinė vaistų kontrolės tarnyba)

chanelle pharmaceuticals manufacturing ltd. (airija) - injekcinis tirpalas - 1 ml tirpalo yra: veikliosios (-iųjų) medžiagos (-ų): ivermektino 10 mg; klorsulono 100 mg. - jaučiams ir pieniniams galvijams (ne laktacijos metu), užsikrėtusiems skrandžio, žarnyno, plaučių, akių nematodais, odos parazitais, sergantiems fasciolioze, gydyti ir profilaktiškai.

Европейский союз - литовский - EMA (European Medicines Agency)

amgen europe b.v. - blinatumomabas - prekursorių ląstelių limfoblastinė leukemija-limfoma - antinavikiniai vaistai - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.

Европейский союз - литовский - EMA (European Medicines Agency)

merck sharp and dohme b.v - posakonazolas - candidiasis; mycoses; coccidioidomycosis; aspergillosis - antimycotics sisteminiam vartojimui - noxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in adults (see sections 4. 2 ir 5. 1):- invasive aspergillosisnoxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections  4. 2 ir 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. atsparumą apibrėžiamas kaip progresavimo infekcija ar nesugebėjimo pagerinti po mažiausiai 7 dienas, prieš terapinės dozės efektyvus priešgrybelinis gydymas. noxafil gastro-resistant tablets are also indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections 4. 2 ir 5. 1):- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis.  noxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adults (see sections 4. 2 ir 5. 1):- invasive aspergillosisnoxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adult and paediatric patients from 2 years of age (see sections 4. 2 ir 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. atsparumą apibrėžiamas kaip progresavimo infekcija ar nesugebėjimo pagerinti po mažiausiai 7 dienas, prieš terapinės dozės efektyvus priešgrybelinis gydymas. noxafil concentrate for solution for infusion is also indicated for prophylaxis of invasive fungal infections in the following adult and paediatric patients from 2 years of age (see sections 4. 2 ir 5. 1):- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease (gvhd) and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis.  noxafil gastro resistant powder and solvent for oral suspension is indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age (see sections 4. 2 ir 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. atsparumą apibrėžiamas kaip progresavimo infekcija ar nesugebėjimo pagerinti po mažiausiai 7 dienas, prieš terapinės dozės efektyvus priešgrybelinis gydymas. noxafil gastro-resistant powder and solvent for oral suspension is indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2  years of age:- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high  risk of developing invasive fungal infections;- haematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high  risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis.  noxafil oral suspension is indicated for use in the treatment of the following fungal infections in adults (see section 5. 1):- invazinių aspergillosis pacientams, sergantiems liga, kuri yra ugniai atsparios į amphotericin b arba itraconazole, arba pacientams, kurie netoleruoja tokių vaistų;- fusariosis pacientams, sergantiems liga, kuri yra ugniai atsparios į amphotericin b, arba pacientams, kurie netoleruoja amphotericin b;- chromoblastomycosis ir mycetoma pacientams, sergantiems liga, kuri yra ugniai atsparios į itraconazole, arba pacientams, kurie netoleruoja itraconazole;- coccidioidomycosis pacientams, sergantiems liga, kuri yra ugniai atsparios į amphotericin b, itraconazole ar fluconazole, arba pacientams, kurie netoleruoja tokių vaistų;- burnos ir ryklės kandidozė: kaip pirmos eilės gydymas pacientams, kurie serga sunkia liga ar yra imuninės sistemos sutrikimų, į kuriuos atsako į aktualius terapija, tikimasi, bus prastas. atsparumą apibrėžiamas kaip progresavimo infekcija ar nesugebėjimo pagerinti po mažiausiai 7 dienas, prieš terapinės dozės efektyvus priešgrybelinis gydymas. noxafil oral suspension is also indicated for prophylaxis of invasive fungal infections in the following patients:- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis.